Acandis GmbH, a pioneering force in the development of stroke solutions, has successfully raised an impressive €52.1 million to further advance its innovative medical device offerings. Established in 2006, this privately held German company has made significant strides in the prevention and treatment of strokes, leveraging cutting-edge engineering expertise to address pressing clinical needs. The recent funding boost will be crucial for Acandis as it aims to expand its comprehensive device portfolio and accelerate ongoing clinical trials, ensuring that patients around the world receive not only safer but also more effective treatment options. With a commitment to fostering a robust culture of innovation, Acandis emphasizes the importance of both youthful energy and seasoned experience among its team members—an essential synergy that drives the company’s rapid growth and success in the fast-evolving medical landscape. The company, headquartered in Pforzheim at the edge of the picturesque Black Forest, is well-positioned to distribute its products globally. As the medical community continuously seeks advancements in stroke care, Acandis remains dedicated to meeting these needs, demonstrating not only the efficacy of its groundbreaking solutions but also reinforcing its role as a key player in neurointerventionalism. This significant funding milestone showcases investors' confidence in Acandis’ vision and capability to shape the future of stroke care, ultimately aimed at improving patient outcomes and enhancing the quality of life for those affected by strokes. For more information, visit www.acandis.com.








